Log In
person
Novavax Inc
NVAX
summarize
2 total product lines
calendar_month
Revenue as of 12/31/2023
| Reporting Segmentarrow_drop_up | Product Line | Amount (USD) | Percentage |
|---|---|---|---|
| keyboard_arrow_right | Reporting Segment & Product Line | Amount (USD) | Percentage |
| Recombinant Vaccines |
Infectious Disease Vaccines
These companies make vaccines targeting infectious diseases.
|
958.71M | 97.46% |
| Recombinant Vaccines |
Patent Licensing to Drug Manufacturers
These companies collect royalties from pharma and biotech companies who make biotech products they developed or products that incorporate their technologies.
|
24.99M | 2.54% |
| keyboard_arrow_down |
Recombinant Vaccines
Infectious Disease Vaccines
|
958.71M | 97.46% |
| keyboard_arrow_right |
These companies make vaccines targeting infectious diseases.
|
||
| keyboard_arrow_down |
Recombinant Vaccines
Patent Licensing to Drug Manufacturers
|
24.99M | 2.54% |
| keyboard_arrow_right |
These companies collect royalties from pharma and biotech companies who make biotech products they developed or products that incorporate their technologies.
|
||